Glaukos (GKOS) Stock Forecast & Price Target

Glaukos Corporation is positioned for significant growth, particularly within its Corneal Health segment, which is projected to expand by 9.4% for FY26, bolstered by improvements in reimbursement for Epioxa in the second half of 2026. The company has experienced a favorable uptick in iDose sales, resulting in enhanced revenue expectations for FY26, with estimates increasing by 3.5% to 5.9%, reflecting a successful ramp-up in patient administration and supportive FDA approval for iDose TR's re-administration. Additionally, Glaukos has achieved a robust gross margin of 85.1%, surpassing investor expectations, and demonstrated operational improvements, as indicated by an operating margin increase of 590 basis points year-over-year, which underscores the company's operational efficiency and revenue-generating potential.

Glaukos Corp has reported mixed financial performance, with domestic glaucoma revenue reaching $86 million, exceeding consensus expectations but showing a decline in growth rate compared to previous quarters. While international glaucoma revenue also beat expectations at $33 million, it revealed a slowdown in growth, indicating potential challenges in sustaining momentum. The company's outlook is further weakened by lowered growth projections for its micro-invasive glaucoma surgery (MIGS) offerings and concerns regarding competitive pressures, slower adoption of new products like iDose, and potential adverse changes in the reimbursement landscape.